IL6 and systemic sclerosis: In fact, in a study observing serum IL-6 levels in SSc patients after rituximab administration, patients had high levels of serum IL-6 at baseline, which decreased remarkably after 6 months following circulating B cells which, evaluated by flow-cytometry, were depleted [38].